Severe Eosinophilic Asthma: Key Decisions That Drive Effective Strategies with Targeted Therapies

Download All
Gain expert guidance on current best practice for the treatment of severe asthma, including an Interactive Decision Support Tool and expert commentaries.
Eileen Wang, MD, MPH
Michael E. Wechsler, MD, MMSc

ClinicalThought

Why determining endotype is crucial to managing severe asthma.

Michael E. Wechsler, MD, MMSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: No longer available for credit

Here’s why targeted biologic therapies are a great advance for treating type 2 asthma.

Eileen Wang, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: September 21, 2020 Expired: No longer available for credit
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation
Sanofi Genzyme and Regeneron Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue